PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL Announces Appointment of PricewaterhouseCoopers LLP as its New Independent Registered Public Accounting Firm
PDL BioPharma Bolsters Management Team
PDL BioPharma Responds to Class Action Lawsuit
PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors
PDL BioPharma Completes Regular Quarterly Dividend Payment